Combination treatment with pioglitazone and metformin is utilized clinically in the treatment of type II diabetes. Treatment with this drug combination reduced the development of aerodigestive cancers in this patient population. Our goal is to expand this treatment into clinical lung cancer chemoprevention. We hypothesized that dietary delivery of metformin/pioglitazone would prevent lung adenoma formation in A/J mice in a benzo[ a]pyrene (B[a]P)-induced carcinogenesis model while modulating chemoprevention and anti-inflammatory biomarkers in residual adenomas. We found that metformin (500 and 850 mg/kg/d) and pioglitazone (15 mg/kg/d) produced statistically significant decreases in lung adenoma formation both as singleagent treatments and in combination, compared with untreated controls, after 15 weeks. Treatment with metformin alone and in combination with pioglitazone resulted in statistically significant decreases in lung adenoma formation at both early-And late-stage interventions. Pioglitazone alone resulted in significant decreases in adenoma formation only at early treatment intervention. We conclude that oral metformin is a viable chemopreventive treatment at doses ranging from 500 to 1,000 mg/kg/d. Pioglitazone at 15 mg/kg/d is a viable chemopreventive agent at earlystage interventions. Combination metformin and pioglitazone performed equal to metformin alone and better than pioglitazone at 15 mg/kg/d. Because the drugs are already FDAapproved, rapid movement to human clinical studies is possible.
|Original language||English (US)|
|Number of pages||8|
|Journal||Cancer Prevention Research|
|State||Published - Feb 2017|
Bibliographical noteFunding Information:
This work was supported by the NCI (Subcontract for Preclinical ContractN01CN25002- 78, Primary Contract Number: Contract #HHSN- 261201200015I, F.G. Ondrey) and the Lions Multiple District 5M Hearing Foundation of Minnesota, (Translational Biomarker Initiatives for Medical Students, F.G. Ondrey).
©2016 American Association for Cancer Research.
Copyright 2017 Elsevier B.V., All rights reserved.